Spoken Alpha
RGNX
REGENXBIO Inc.
Overview
REGENXBIO Inc is a Healthcare company operating in Biotechnology with a $563.1M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q2 FY2026Earnings2026-08-0614 Q&A exchanges
- Q1 FY2026Earnings2026-05-1414 Q&A exchanges
- Q4 FY2025Earnings2026-03-0513 Q&A exchanges
- Q3 FY2025Earnings2025-11-0617 Q&A exchanges
- Q1 FY2025Earnings2025-05-1323 Q&A exchanges
- Q4 FY2024Earnings2025-03-1322 Q&A exchanges
- Q3 FY2024Earnings2024-11-0623 Q&A exchanges
- Q2 FY2024Earnings2024-08-0127 Q&A exchanges
- Q1 FY2024Earnings2024-05-0812 Q&A exchanges
- Q4 FY2023Earnings2024-02-2721 Q&A exchanges
- Q3 FY2023Earnings2023-11-0815 Q&A exchanges
- Q2 FY2023Earnings2023-08-0221 Q&A exchanges
- Q1 FY2023Earnings2023-05-0313 Q&A exchanges
- Q4 FY2022Earnings2023-02-2817 Q&A exchanges
- Q3 FY2022Earnings2022-11-0311 Q&A exchanges
- Q2 FY2022Earnings2022-08-0522 Q&A exchanges
- Q1 FY2022Earnings2022-05-049 Q&A exchanges
- Q4 FY2021Earnings2022-03-0114 Q&A exchanges
- Q3 FY2021Earnings2021-11-028 Q&A exchanges
- Q2 FY2021Earnings2021-08-098 Q&A exchanges
- Q1 FY2021Earnings2021-05-057 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-04EPS— vs $-1.36—Rev— vs ——EODHD
- Q2 FY20262026-08-05EPS$0.43 vs $0.12+100.0%Rev$108.0M vs ——EODHD
- Q1 FY20262026-05-13EPS$-1.72 vs $-1.41-22.0%Rev$6.4M vs ——EODHD
- Q4 FY20252026-03-04EPS$-1.30 vs $-0.72-80.7%Rev$30.3M vs ——EODHD
- Q3 FY20252025-11-05EPS$-1.20 vs $-1.30+7.7%Rev$29.7M vs ——EODHD
- Q2 FY20252025-08-06EPS$-1.38 vs $-1.13-22.1%Rev$21.4M vs ——EODHD
- Q1 FY20252025-05-11EPS$0.12 vs $0.49-75.5%Rev$89.0M vs ——EODHD
- Q4 FY20242025-02-24EPS$-1.01 vs $-1.08+6.9%Rev$21.2M vs ——EODHD
- Q3 FY20242024-11-05EPS$-1.17 vs $-1.10-6.4%Rev$24.2M vs ——EODHD
- Q2 FY20242024-07-31EPS$-1.05 vs $-1.31+19.9%Rev$22.3M vs ——EODHD
- Q1 FY20242024-05-07EPS$-1.34 vs $-1.26-6.3%Rev$15.6M vs ——EODHD
- Q4 FY20232024-02-26EPS$-1.43 vs $-1.27-12.6%Rev$22.2M vs ——EODHD
- Q3 FY20232023-11-07EPS$-1.41 vs $-1.52+7.2%Rev$28.9M vs ——EODHD
- Q2 FY20232023-08-01EPS$-1.66 vs $-1.21-37.2%Rev$20.0M vs ——EODHD
- Q1 FY20232023-05-02EPS$-1.53 vs $-1.41-8.5%Rev$19.1M vs ——EODHD
- Q4 FY20222023-02-27EPS$-1.38 vs $-1.23-12.2%Rev$31.3M vs ——EODHD
- Q3 FY20222022-11-02EPS$-1.75 vs $-1.46-19.9%Rev$26.5M vs ——EODHD
- Q2 FY20222022-08-02EPS$-1.58 vs $-1.54-2.6%Rev$32.6M vs ——EODHD
- Q1 FY20222022-05-03EPS$-1.79 vs $-1.28-39.8%Rev$22.2M vs ——EODHD
- Q4 FY20212022-02-28EPS$6.67 vs $4.71+41.6%Rev$398.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-1.36 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $0.43 | $0.12 | +100.0% | $108.0M | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-1.72 | $-1.41 | -22.0% | $6.4M | — | — | EODHD |
| Q4 FY2025 | 2026-03-04 | $-1.30 | $-0.72 | -80.7% | $30.3M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-1.20 | $-1.30 | +7.7% | $29.7M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-1.38 | $-1.13 | -22.1% | $21.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $0.12 | $0.49 | -75.5% | $89.0M | — | — | EODHD |
| Q4 FY2024 | 2025-02-24 | $-1.01 | $-1.08 | +6.9% | $21.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-1.17 | $-1.10 | -6.4% | $24.2M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-1.05 | $-1.31 | +19.9% | $22.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-1.34 | $-1.26 | -6.3% | $15.6M | — | — | EODHD |
| Q4 FY2023 | 2024-02-26 | $-1.43 | $-1.27 | -12.6% | $22.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-1.41 | $-1.52 | +7.2% | $28.9M | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $-1.66 | $-1.21 | -37.2% | $20.0M | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $-1.53 | $-1.41 | -8.5% | $19.1M | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $-1.38 | $-1.23 | -12.2% | $31.3M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-1.75 | $-1.46 | -19.9% | $26.5M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $-1.58 | $-1.54 | -2.6% | $32.6M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-1.79 | $-1.28 | -39.8% | $22.2M | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $6.67 | $4.71 | +41.6% | $398.7M | — | — | EODHD |
Source: EODHD. RGNX reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Curran SimpsonCEO2 yr 2 mo9 callsCurrent
- Mitchell ChanCFO2 yr4 callsCurrent
- Craig MalzahnChief Technology Officer1 yr 6 mono recorded callsCurrent
- Steve PakolaChief Medical Officer7 yr 5 mo19 callsCurrent
- Patrick J ChristmasChief Strategy & Legal Officer1 yr 1 mo20 callsCurrent
- Kenneth T MillsCEO8 yr 4 mo13 callsFormer
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RGNX.
$ curl https://api.spokenalpha.com/v1/companies/RGNXFAQ
Frequently asked about RGNX
Where can I find REGENXBIO Inc.'s (RGNX) earnings call transcripts?
Spoken Alpha indexes RGNX's earnings call transcripts at https://spokenalpha.com/companies/RGNX. Each call links to attributed speakers and parsed analyst Q&A. REGENXBIO Inc.'s own investor relations page is at https://ir.regenxbio.com/.
When was REGENXBIO Inc.'s most recent earnings call?
REGENXBIO Inc. (RGNX) held its most recent earnings call on 2026-08-06, covering fiscal Q2 2026.
What sector is RGNX in?
REGENXBIO Inc. (RGNX) operates in the Healthcare sector (Biotechnology industry).